Skip to main content

Table 5 Member States of the WHO European region reporting on surveillance-related activities by EU/EEA membership

From: Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014)

  EU/EEA non-EU/EEA  
  N = 25 % N = 19 % p-value
National coordination      
 Existence of a written national strategy or plan that focuses exclusively or primarily on the prevention and control of viral hepatitis and includes a surveillance component 6 24.0 6 31.6 0.412
Routine surveillance of viral hepatitis B and C      
 National surveillance system for acute HBV 25 100 18 94.7 0.432
 National surveillance system for acute HCV 23 92.0 18 94.7 0.604
 National surveillance system for chronic HBV 18 72.0 10 52.6 0.157
 National surveillance system for chronic HCV 17 68.0 10 52.6 0.234
 Standard case definitions for viral hepatitis infections 25 100 17 89.5 0.181
 Regular hepatitis disease reports published 22 88.0 17 89.5 0.632
 Hepatitis outbreaks required to be reported to the government and further investigated 23 92.0 19 100 0.317
 Adequate laboratory capacity nationally to support hepatitis outbreak investigations and other surveillance activities for HBV and HBC 25 100 19 100 -
Other sources of strategic information and capacities for disease burden estimation      
 Deaths, including from hepatitis, reported to a central registry 25 100 17 89.5 0.181
 Liver cancer cases registered nationally 22 88.0 13 68.4 0.122
 Cases of HIV/hepatitis co-infection registered nationally 16 64.0 13 68.4 0.508
 Viral hepatitis serosurveys conducted regularly 10 40.0 10 52.6 0.299
  If yes, please specify the target populations:      
   - children 3 12.0 2 10.5 0.632
   - general population 8 32.0 3 15.8 0.191
   - people who inject drugs 6 24.0 6 31.6 0.412
   - men who have sex with men 3 12.0 6 31.6 0.112
   - other groups 7 28.0 10 52.6 0.089
 All pregnant women screened for HBV 21 84.0 13 68.3 0.195
 All donated blood (including family donations) screened for HBV 25 100 17a 94.4 0.419
 All donated blood (including family donations) screened for HCV 25 100 18a 100 0.432
Areas in which Member States might want assistance from WHO      
 National plan 6 24.0 11 57.9 0.024
 Surveillance 2 8.0 8 42.1 0.010
 Burden estimation 6 24.0 9 47.4 0.097
  1. aAndorra is not included in this calculation because Andorra does not have blood donation centres